WPD Pharmaceuticals Inc. is a biotechnology research and development company primarily focused on oncology and virology, specializing in the development of targeted therapeutics for brain glioma and other central nervous system cancers. The company conducts research on biological compounds and small molecules with the aim of advancing medicinal products in these areas. WPD has licensed nine novel drug candidates in select countries, with four currently in clinical development. It maintains collaborative relationships with leading academic medical institutions, including Wake Forest University and hospitals in Poland. While historically engaged in active pharmaceutical R&D, WPD Pharmaceuticals presently holds shares in its former Polish subsidiary following a corporate restructuring and is exploring new opportunities in the biotech sector. Headquartered in Vancouver, Canada, the company continues to play a role within the specialized field of biotechnology focused on CNS oncology therapies.